Artesunate- mefloquine

Artesunate- mefloquine

Access
-
Approved
ASMQ
Cipla
3-day cure, artemisinin-based combination therapies (TPP-1)
Therapeutic indication
  • Treatment of uncomplicated¬†P. falciparum¬†malaria in adults, children and infants >5 kg

Dosing
  • Once-daily for 3 days

Efficacy
  • 28-day PCR-corrected ACPR* 96.2%

Key features
  • Long post-treatment protection

  • 3-year shelf life

Challenges
  • Mefloquine active pharmaceutical ingredient costs contribute to high price of finished product
  • Only one prequalified manufacturer
Status
  • Registered by Cipla in 10 countries
  • Prequalified in 2012
  • >1.3 million treatments distributed since 2012
  • Key role in areas of drug resistance containment in Greater Mekong Sub-region
Previously
  • Developed by FACT Consortium (led by DNDi¬†and TDR) with Farmanguinhos and transferred to Cipla for manufacture in Asia and to secure WHO prequalification in 2012. Incorporated into MMV portfolio in 2015

Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response